Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting
December 07, 2019 14:45 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics to Present at Upcoming Investor Conference
November 15, 2019 07:30 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics Reports Third Quarter 2019 Financial Results
November 12, 2019 16:30 ET
|
Unum Therapeutics Inc.
- Progress towards focusing on solid tumors remains on track with enrollment and early safety updates from Phase 1 trial of ACTR707 in HER2+ cancers expected by the end of this year- CAMBRIDGE,...
Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 05, 2019 08:30 ET
|
Unum Therapeutics Inc.
- Unum’s first product candidate from its BOXR platform, BOXR1030, is designed to improve T cell functionality in the solid tumor microenvironment - - BOXR1030 T cells co-express the GOT2...
Unum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers
November 04, 2019 16:00 ET
|
Unum Therapeutics Inc.
- Solid tumor cancers represent the greatest unmet medical need for targeted cell therapies; Unum’s goals are to more selectively target solid tumors with its ACTR platform candidates and improve T...
Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting
October 02, 2019 07:05 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics to Present at Upcoming Industry Conferences in September
September 05, 2019 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics to Present at Upcoming September Investor Conferences
August 26, 2019 07:05 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Updates
August 12, 2019 16:05 ET
|
Unum Therapeutics Inc.
- Updated results from Phase 1 trial with ACTR707 in combination with rituximab in adults with relapsed/refractory non-Hodgkin lymphoma confirms the clinical activity achieved in previous cohorts with...
Unum Therapeutics to Review Second Quarter 2019 Financial Results on August 12, 2019
August 02, 2019 09:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing potentially curative cellular immunotherapies through its...